Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor Journal Article


Authors: Nieborowska-Skorska, M.; Paietta, E. M.; Levine, R. L.; Fernandez, H. F.; Tallman, M. S.; Litzow, M. R.; Skorski, T.
Article Title: Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor
Keywords: clinical article; controlled study; gene mutation; human cell; doxorubicin; drug efficacy; protein tyrosine kinase; cancer inhibition; drug mechanism; leukemia cell; drug response; western blotting; clonogenic assay; drug sensitivity; cd34 selection; cell activity; olaparib; transcription factor runx1; core binding factor; acute myeloid leukemia; human; priority journal; article; avapritinib; protein cbfa2t1
Journal Title: Blood Advances
Volume: 3
Issue: 23
ISSN: 2473-9529
Publisher: American Society of Hematology  
Date Published: 2019-12-10
Start Page: 4050
End Page: 4054
Language: English
DOI: 10.1182/bloodadvances.2019000756
PUBMED: 31816060
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Martin Stuart Tallman
    478 Tallman
  2. Ross Levine
    520 Levine